Despite this broad range of potential therapeutic applications, only two AR ligands have been approved: theA2A antagonist Istradefylline, approved for the treatment of Parkinson’s disease, and the A2A agonist Regadenoson, used as a coronary vasodilator. The gene discussed is AR; the disease is Parkinson disease.